How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moraxella-catarrhalis-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moraxella Catarrhalis Pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moraxella Catarrhalis Pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moraxella Catarrhalis Pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ketek	TELITHROMYCIN	Sanofi	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Moraxella Catarrhalis Pneumonia
Lg Chem Ltd · 2 drugs in Moraxella Catarrhalis Pneumonia
Assistance Publique - Hôpitaux de Paris · 1 drug in Moraxella Catarrhalis Pneumonia
Bayer AG · 1 drug in Moraxella Catarrhalis Pneumonia
Dr Reddys Labs Inc · 1 drug in Moraxella Catarrhalis Pneumonia
Generic (originally Abbott/AbbVie) · 1 drug in Moraxella Catarrhalis Pneumonia
Generic (originally Beecham/GSK) · 1 drug in Moraxella Catarrhalis Pneumonia
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Moraxella Catarrhalis Pneumonia
King George's Medical University · 1 drug in Moraxella Catarrhalis Pneumonia
Allergan · 1 drug in Moraxella Catarrhalis Pneumonia
Merck & Co. · 1 drug in Moraxella Catarrhalis Pneumonia
Novartis Pharmaceuticals · 1 drug in Moraxella Catarrhalis Pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moraxella Catarrhalis Pneumonia:

Cite this brief

Drug Landscape (2026). Moraxella Catarrhalis Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moraxella-catarrhalis-pneumonia. Accessed 2026-06-10.

Moraxella Catarrhalis Pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing